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Motor neurons in ALS die via cell-autonomous and non-cell-autonomous mechanisms. Using adult human
astrocytes and motor neurons, Re et al. (2014), in this issue of Neuron, discover that familial and sporadic
ALS-derived human adult astrocytes secrete neurotoxic factors that selectively kill motor neurons through
necroptosis, suggesting a new therapeutic avenue.Amyotrophic lateral sclerosis (ALS),
commonly referred to as Lou Gehrig’s
disease, is an adult-onset neurodegener-
ative disease manifested by degenera-
tion of motor neurons in motor cortex,
brain stem, and spinal cord, resulting in
muscle paralysis and ultimately death
(Rowland and Shneider, 2001). While
the disease is dominantly inherited in
approximately 10% of patients (termed
familial), most often the disease is spo-
radic, with largely unknown genetic etiol-
ogy. Numerous hypotheses have been
proposed to account for the disease-
associated motor neuron loss, including
conformational instability of proteins
triggering neurotoxicity, perturbations of
RNA processing, mitochondrial dysfunc-
tion, defective axonal transport, excito-toxicity, and inflammation (reviewed in
(Rothstein, 2009). However, the precise
molecular mechanism(s) that target mo-
tor neurons for death and result in the
pathological manifestations still remain
elusive. Studies reporting mutations in
the SOD1 gene encoding the antioxidant
enzyme Cu/Zn superoxide dismutase-1
provided the first genetic link to ALS
(Rosen et al., 1993). Since then, studies
have implicated both cell-autonomous
and non-cell-autonomous mechanisms
in SOD1-mediated toxicity (Clement
et al., 2003). The identity of such cell
types that modulate motor neuron sur-
vival came from studies using cultured
motor neurons derived from embryonic
spinal cord or differentiated from embry-
onic stem cells (Di Giorgio et al., 2008;Marchetto et al., 2008; Nagai et al.,
2007). In these studies, cocultured motor
neurons were less likely to survive when
they were on astrocytes that express
mutant SOD1. Exposure of cultured mo-
tor neurons to conditioned media derived
from astrocytes also affected survival of
motor neurons, probably through soluble
factors released by mutant SOD1-
expressing astrocytes. In coculture sys-
tems with motor neurons, astrocytes
derived from sporadic ALS (sALS) post-
mortem spinal cord neural progenitor
cells (NPCs) also selectively killed motor
neurons (Haidet-Phillips et al., 2011),
suggesting a shared astrocyte-depen-
dent disease mechanism between famil-
ial and sporadic forms of ALS. While
these studies point to astrocytes as81, March 5, 2014 ª2014 Elsevier Inc. 961
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neuron damage, the mechanism underly-
ing astrocyte-mediated toxicity toward
motor neurons has remained ambiguous.
In this issue of Neuron, Re et al. (2014)
report that human adult astrocytes
derived from motor cortex and spinal
cord of sALS patients have detrimental
effects on human embryonic stem-cell-
derived motor neurons by triggering a
form of regulated necrosis, termed nec-
roptosis. By contrast, survival of these
motor neurons was not affected by
astrocytes derived from patients with
Alzheimer’s disease or chronic obstruc-
tive respirator disorder (COPD). Cocultur-
ing motor neurons with other cell types
like fibroblasts did not have any marked
effect on their survival either. Further-
more, nonmotor neuron cell types of
GABAergic origin were also unaffected
by sALS-derived astrocytes. Thus, in line
with previous studies, there seems to be
selective vulnerability of motor neurons
to astrocyte-mediated toxicity in sALS.
In transgenic familial ALS (fALS) mouse
models, SOD1 mutations result in ALS-
like phenotypes even in the presence
of endogenous SOD1, suggesting that
gain of toxic functions plays a causal role
in the disease. Accordingly, shRNA-medi-
ated knockdown of SOD1 in fALS
astrocytes fully rescuesmotor neuron-tar-
geted toxicity (Haidet-Phillips et al., 2011).
Previous studies also argued for a patho-
genic role for wild-type (WT) SOD1 toward
motor neuron survival in sALS, potentially
through aberrant posttranslational modifi-
cations of WT SOD1 that may cause it to
undergo conformational changes and
aggregate (Rotunno and Bosco, 2013;
Deng et al., 2006). Re et al. (2014) test
this possibility by knocking down WT
SOD1 in sALS astrocytes independently
using four different shRNA constructs
and examining the resulting effect on sur-
vival of motor neurons. Surprisingly, loss
of motor neurons was not mitigated by
knockdown of WT SOD1 in sALS astro-
cytes under these conditions. Astrocyte-
targeted silencing of TAR DNA-binding
protein 43 (TDP 43), mutations that have
been genetically linked to ALS, also failed
to mitigate motor neuron degeneration.
Furthermore, survival of cultured motor
neurons was affected by exposure to me-
dia conditioned for 7 days with sALS-
derived astrocytes that induced signs of962 Neuron 81, March 5, 2014 ª2014 ElsevieDNA fragmentation, caspase-3 activation,
and loss of plasma membrane integrity.
These observations suggest that motor
neurondeathwasmediated by the release
of soluble factors specific to sALS astro-
cytes. Next, Re et al. (2014) provide
evidence that sALS-dervied, as well as
fALS-derived, astrocytes kill motor neu-
rons through a Bcl-2-associated X (Bax)
protein-dependent death pathway. Bax
is a mitochondrially translocated pro-
apoptotic protein that induces cell death
in response to apoptotic stimuli by per-
meabilizing the outer mitochondrial
membrane, which results in release of
cytochromeCand activation of caspases.
However, Re et al. (2014) show that while
Bax inhibition protects motor neurons
exposed to sALS astrocytes, pharma-
cological inhibition of the initiator cas-
pase-8 or executioner caspase-3 and
caspase-7 that are activated downstream
of cytochrome C release did not pro-
mote survival of motor neurons. Thus, it
appears that sALS astrocyte-triggered
death of motor neuron is mediated by
Bax in a caspase-independent manner.
Such Bax-dependent toxicity also seems
to underlie fALS-mediated motor neuron
death, as primary mouse motor neurons
lacking Bax are resistant to mutant
SOD1-induced toxicity in this study.
While activation of apoptotic pathways
have been long implicated in the demise
of motor neurons in ALS, it is becoming
increasingly clear that apoptosis is not
the only cellular mechanism that regulates
cell death. Necrotic cell death, traditionally
viewed as a passive process, is now gain-
ing recognition, at least in part, as a cell
deathprogram (Galluzzi et al., 2012). There
are different forms of necrotic cell death
that are defined biochemically. While cas-
pases are executioners of apoptosis, they
play no positive role in necrotic cell death.
Re et al. (2014) show that in the absence
of caspase activation, motor neuron
demise triggered by sALS as well as fALS
astrocytes might involve necroptosis, a
specialized form of necrotic cell death
that involves the activation of the kinase
domain of receptor-interacting protein 1
(RIP1) and subsequent recruitment of a
mixed lineage kinase domain-like protein
(MLKL) (Kaczmarek et al., 2013). Re et al.
(2014) show that treatment of motor
neuron/astrocyte cocultures with the tryp-
tophan-based allosteric inhibitor of RIP1,r Inc.necrostatin-1 (Nec-1), or RIP1-specific
shRNA prevented the fALS and sALS
astrocyte-induced loss of motor neurons.
They observe similar neuroprotective
effects toward motor neurons when
MLKLwas pharmacologically inhibited us-
ing necrosulfanamide (NSA) (Figure 1). In
Parkinson’s disease (PD), parthanatos,
another necrotic cell death program, plays
a role in the demise of dopamine neurons
(Lee et al., 2013). Thus, nontraditional cell
deathmechanismsareemergingas impor-
tant players in chronic neurodegenerative
diseases. Since the pharmaceutical focus
on conventional cell death pathways has
not been fruitful asdisease-modifying ther-
apies, it will be important to determine
whether these necrotic programmed cell
deathpathwaysmodifyALS,PD, andother
neurodegenerative diseases in humans.
Although familial and sporadic forms of
ALS have common disease pathologies, a
major challenge in ALS research has been
to evaluate similarities and differences
in the mechanisms that cause the detri-
mental effects in the respective scenarios.
The development of humanized ALS
models from patients afflicted with the
disease of known and unknown etiology
has helped make strides toward this
end. For instance, together with earlier
studies, the findings from Re et al. (2014)
identify astrocytes, the largest population
of cells in the CNS, to have toxic non-cell-
autonomous effects on motor neurons in
both forms of ALS. Astrocytes closely
interact with neurons and when activated
by neuronal insults proliferate and exhibit
morphological and gene expression
changes. This phenomenon, referred to
as astrogliosis, is a hallmark feature of
ALS. Thus, the presence of reactive astro-
cytes in the motor neuron vicinity poses
similar pathological challenges in both
forms of ALS. Additionally, both forms of
ALS are mediated by release of astro-
cyte-specific toxic factors that target mo-
tor neurons. Identification of such astro-
cyte-derived factors can have far
reaching implications in terms of patho-
genesis and therapeutic interventions.
Few earlier studies have attempted to
identify such soluble mediators of cellular
toxicity but with little success. Di Giorgio
et al. (2008) identified prostaglandin D2
(PGD2) as an astrocyte-derived mediator
of motor neuron death in sALS. However,
blocking PGD2 has offered only modest
Figure 1. Non-Cell-Autonomous Mediators of Cell Death Derived from Activated Astrocytes
Contribute to Necroptosis-Mediated Motor Neuron Demise
Presence of mutant SOD1 in astrocytes derived from familial ALS patients affect motor neuron viability
through secretion of neurotoxic factors that target motor neurons for death. Through comparative analysis
of astrocytes derived from familial and sporadic ALS patients, Re et al. (2014) show that the secretion of
such toxic factors may not be triggered by mutant SOD1 per se. Rather, astrocyte-derived factors induce
motor neuron death via necroptosis involving RIP1 and MLKL under both conditions. Accordingly, phar-
macological inhibition of RIP1 andMLKL using necrostatin (Nec-1) and necrosulfanamide (NSA) promotes
motor neuron survival. While the identity of such motor neuron-specific neurotoxins is yet to be verified,
this finding offers new insight into ALS pathogenesis.
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the involvement of additional factors in
this pathway. In a study by Marchetto
et al. (2008), activation of inflammatory
responses in fALS-derived astrocytes
was observed with concomitant increase
in reactive oxygen species (ROS) and
proinflammatory cytokines like nitric ox-
ide. NF-KB and kinase (MAPK, JNK, and
AKT) signaling pathways are also acti-
vated in fALS and sALS astrocytes (Hai-
det-Phillips et al., 2011). The identification
of necroptosis-mediated cell death as a
common feature of fALS and sALS further
necessitates the identification of factors
and processes that serve as initiators,
modulators, or executioners of necropto-
sis in the context of ALS.
The identification of astrocytes asmotor
neuron killers has important implications
for stem-cell-based therapies for ALS.
Given the toxic effects motor neurons
endure, replacement of damaged motor
neurons with wild-type neurons may
appear as a promising repair strategy.
However, engraftment of healthy motor
neurons onto to ALS spinal cord that har-
bors a hostile cellular milieu surroundedby damaged astrocytes may not have
beneficial effects. The presence of mutant
SOD1 in astrocytesmarked themasmedi-
ators of motor neuron-targeted toxicity.
However, failure to rescue motor neuron
loss by SOD1 suppression in both fALS
and sALS raises a number of interesting
questions for further investigation. For
instance, what are the cell-autonomous
and non-cell-autonomous stimuli that
activate astrocytes culminating in motor
neuron demise? Re et al. (2014) show
that GABAergic interneurons are spared
from astrocyte-mediated toxicity. Howev-
er, ventrolateral and mediolateral spinal
interneurons are also known to degen-
erate in ALS prior to motor neuron loss
(Martin et al., 2007). This raises questions
about other cell types that are susceptible
to astrocytes that are on an attack
rampage. The availability of humanized
ALS coculture systems is advantageous
to study the exclusive contribution of as-
trocytes (or perhaps other suspected cell
types) without any interference from other
cell types. However, in light of the fact that
secreted soluble factors aremediating the
toxic effects in motor neurons, it promptsNeuronthe question whether these factors origi-
nate exclusively from astrocytes or
whether they can be derived from other
cell types that are also susceptible to
astrocytes. Future complementary work
using in vitro culture systems and animal
models will hopefully help identify bio-
markers for diagnosis and screen for
drugs that have neuroprotective effects
with potential clinical relevance with re-
gards to ALS.
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